A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Recruiting

Phase 2

EnsifentrineA Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Sponsor:

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Code:

NCT06559150

Conditions

Non-cystic Fibrosis Bronchiectasis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Nebulized Ensifentrine Suspension; 3 mg

Nebulized Placebo Solution

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-03. This information was provided to ClinicalTrials.gov by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA on 2026-05-13.